NCT05247957

NKG2D CAR-NK Cell Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Terminated NA Last updated 13 January 2023

What this trial tests

NA trial testing CAR-NK cells in Safety and Efficacy in 9 participants. Terminated before completion.

Timeline

13 October 2021

Primary endpoint
12 December 2022

20 December 2022

Quick facts

Lead sponsor	Hangzhou Cheetah Cell Therapeutics Co., Ltd
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	13 October 2021
Primary completion	12 December 2022
Estimated completion	20 December 2022
Sites	1 location across China

Drugs / interventions tested

• CAR-NK cells — full drug profile →

Conditions studied

• Safety and Efficacy — all drugs for Safety and Efficacy →

Sponsor

Hangzhou Cheetah Cell Therapeutics Co., Ltd — full company profile →

Who can join

Adults 10 to 75, any sex, with Safety and Efficacy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial will explore the maximum tolerated dose of cord blood NKG2D CAR-NK in the treatment of recurrent refractory acute myeloid leukemia in a dose-escalation manner, and observe its clinical safety and efficacy.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Natural killer cells in antitumour adoptive cell immunotherapy.
   Laskowski TJ, Biederstädt A, Rezvani K. · · 2022 · cited 547× · PMID 35879429 · DOI 10.1038/s41568-022-00491-0
2. Exploring treatment options in cancer: Tumor treatment strategies.
   Liu B, Zhou H, Tan L, Siu KTH, et al · · 2024 · cited 536× · PMID 39013849 · DOI 10.1038/s41392-024-01856-7
3. Natural killer cell homing and trafficking in tissues and tumors: from biology to application.
   Ran GH, Lin YQ, Tian L, Zhang T, et al · · 2022 · cited 207× · PMID 35768424 · DOI 10.1038/s41392-022-01058-z
4. CAR-T: What Is Next?
   Chen YJ, Abila B, Mostafa Kamel Y. · · 2023 · cited 160× · PMID 36765623 · DOI 10.3390/cancers15030663
5. Allogeneic natural killer cell therapy.
   Berrien-Elliott MM, Jacobs MT, Fehniger TA. · · 2023 · cited 153× · PMID 36416736 · DOI 10.1182/blood.2022016200
6. Development of NK cell-based cancer immunotherapies through receptor engineering.
   Page A, Chuvin N, Valladeau-Guilemond J, Depil S. · · 2024 · cited 123× · PMID 38443448 · DOI 10.1038/s41423-024-01145-x
7. Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization.
   Chen S, Zhu H, Jounaidi Y. · · 2024 · cited 106× · PMID 39511139 · DOI 10.1038/s41392-024-02005-w
8. Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia.
   Caruso S, De Angelis B, Del Bufalo F, Ciccone R, et al · · 2022 · cited 90× · PMID 36335396 · DOI 10.1186/s13045-022-01376-3